AI to screen 3,000 men for hidden cancers in beijing pilot
NCT ID NCT07319923
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to build and test an AI-based early warning system to screen men aged 50 and older for prostate and bladder cancer. Researchers will enroll 3,000 male residents of Beijing, measuring PSA levels and using AI to flag high-risk individuals. No drugs or devices are given—the goal is to see if a coordinated screening pathway from community clinics to hospitals can catch cancers earlier and improve follow-up.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could create a practical, AI-driven screening pathway that catches prostate and bladder cancers earlier in community settings, potentially reducing deaths.
What could go wrong
This is an observational study—no treatment is tested. The AI system may not improve detection rates or be scalable to other populations. Results are years away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Urology, Peking University First Hospital, Beijing, 100034
RECRUITINGBeijing, China
Contact Email: •••••@•••••